Margin rebounds sequentially, but higher costs limit profit growth
Revenue rose 34.82% year on year, yet faster expense growth, higher interest and depreciation kept net-profit growth to 5.70%.
Filed 14 Aug 2026, 09:58 IST · Anupam Rasayan India Ltd (ANURAS)
Key takeaways
- Consolidated net profit rose only 5.70% year on year to Rs 51.22 cr as expenses grew faster than revenue and interest increased 37.94%.
- Operating margin recovered 3.20 percentage points sequentially to 24.79%, but remained 0.79 percentage points below Q1FY26.
- Other income contributed 18.03% of pre-tax profit, while the sequential tax-rate increase of 26.37 percentage points cut net profit despite higher pre-tax profit.
Price around the results
Revenue growth did not translate into comparable profit growth
Consolidated revenue increased 34.82% year on year and 3.02% sequentially, but net profit grew only 5.70% year on year and declined 8.54% sequentially. Year-on-year expenses rose 36.25%, outpacing revenue, while interest increased 37.94% and depreciation rose 82.72%. Sequentially, expenses fell 1.18% and operating profit rose 18.27%, but the higher tax rate reduced net profit.
Margin improved from Q4FY26 but stayed below last year
Operating margin expanded 3.20 percentage points sequentially because revenue grew while expenses declined. It was still 0.79 percentage points lower than in Q1FY26, reflecting the year-on-year cost increase ahead of revenue growth. The margin path remains uneven: it moved from 28.88% in Q4FY25 to 18.57% in Q2FY26, then 24.88%, 21.59% and 24.79% over the following quarters.
Profit quality was affected by other income and tax movements
Other income accounted for 18.03% of pre-tax profit, making reported profit less dependent on operating earnings than the headline operating result suggests. The tax rate rose to 26.5% from 0.13% sequentially and 22.9% a year earlier, limiting the conversion of higher operating profit into net profit. Operating margin was 6.63 percentage points above the 18.16% median of 81 reported Commodities-sector peers.
New orders and capacity additions broaden the stated growth pipeline
Management said the company completed its acquisition of U.S.-based Jayhawk Fine Chemicals during the quarter to expand its manufacturing footprint and CDMO platform. The company said it had signed a 10-year Letter of Intent with BASQUEVOLT worth Rs 2,850 cr and that the agreement represents an approximate US$300 million revenue opportunity over 10 years; it also cited a five-year, Rs 3,000 cr Letter of Intent with Elementium. Management said Tanfac had increased capacity through process improvement and debottlenecking, while the presentation flags future expansion in fluorination products and one new pharmaceutical intermediate.
The initial stock move was modest versus its results history
The stock was up 0.60% on the reaction day, with a 0.51% opening gap and a 2.81-times volume ratio. That move was smaller than the 2.69% median absolute move after the past eight results, when the stock rose five times and fell three times. The reaction was therefore relatively muted despite elevated volume.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹655 cr | ₹636 cr | +3.02% | +34.82% |
| Other income | ₹13 cr | ₹3 cr | +272.70% | +155.80% |
| Expenses | ₹493 cr | ₹498 cr | -1.18% | +36.25% |
| Operating profit | ₹162 cr | ₹137 cr | +18.27% | +30.65% |
| Operating margin (%) | 24.79% | 21.59% | — | — |
| Interest | ₹49 cr | ₹42 cr | +17.37% | +37.94% |
| Depreciation | ₹56 cr | ₹43 cr | +31.35% | +82.72% |
| Profit before tax | ₹70 cr | ₹56 cr | +24.27% | +10.87% |
| Tax | ₹18 cr | ₹0 cr | +26285.71% | +28.35% |
| Net profit | ₹51 cr | ₹56 cr | -8.54% | +5.70% |
| EPS (₹) | ₹3.39 | ₹3.75 | -9.60% | +9.35% |
Operating margin of 24.79% compares with a Commodities sector median of 18.16% across 81 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +0.60% | +0.72% |
Volume on the results session was 2.81× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company successfully completed the acquisition of Jayhawk Fine Chemicals during the quarter.
Guidance & outlook
- The BASQUEVOLT agreement represents an approximate US$300 million revenue opportunity over ten years.
- The company remains confident in its growth prospects and aims to deliver sustainable growth and long-term value creation.
Expansion
- The company acquired U.S.-based Jayhawk Fine Chemicals to expand its manufacturing footprint and CDMO platform.
- Tanfac increased capacities of its existing product portfolio through process improvement and debottlenecking.
- The company identifies future expansion of its fluorination product series as a key rationale for Tanfac.
New orders
- Anupam signed a ten-year Letter of Intent with BASQUEVOLT, S.A. worth ₹2,850 crore, to be commercialized in FY27.
- Anupam signed a five-year Letter of Intent with Elementium worth ₹3,000 crore, to be commercialized in FY27.
New products
- The pharmaceutical segment added one new intermediate for a new drug to its portfolio.
New initiatives
- The company became the first globally to commercialize ETFA using flow chemistry, strengthening its complex fluorination capabilities.
What to watch
- Whether operating margin holds above 24.79% after the sequential recovery.
- Whether expenses continue to grow no faster than revenue after the 36.25% year-on-year expense increase.
- The contribution from the BASQUEVOLT and Elementium initiatives, which management said are to be commercialized in FY27.